Abivax stock jumps after clinical trial milestone

Abivax SA

10/01/2025 08:40

** Shares in Abivax  ABVX.PA  gain as much as 8.8% after the
enrolment in the phase 3 ABTECT trial for its obefizamod
medicine surpassed 1,000 participants
** Enrolment completion is expected in Q2 2025 and top-line
results for 8-week induction trial in Q3 2025
** Kempen Daily analysts call the drug treating ulcerative
colitis "grossly undervalued" and predict it to be the preferred
oral option once it hits the market
** Portzamparc does not see a delay in trial results having
serious impact and forecasts a filing as early as H2 2026
** As of 0833 GMT, the shares are up 7.3%

 (Reporting by Jakob Van Calster)
 ((Jakob.vancalster@thomsonreuters.com))